LSI Lifeline Sci. S

TIDMLSI

RNS Number : 5973Z

Lifeline Scientific, Inc

19 March 2012

19 March 2012

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Admission of shares and TVR

Lifeline Scientific, the medical technology company focused on the worldwide commercialisation of its LifePort Kidney Transporter, a product designed to address the global challenge of human donor organ shortages, on 15 March 2012 transferred 427,132 common shares of $0.01 each from Regulation S restricted stock to unrestricted stock. Admission is expected to occur tomorrow.

Lifeline has 19,424,959 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 19,424,959.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FSA's Disclosure and Transparency Rules.

Following this transfer, 6,851,217 common shares remain subject to Regulation S restrictions and are held in certificated form only. These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.

The remaining 12,573,742 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.

Enquiries:

 
 Lifeline Scientific, Inc.     + 001 847 294 0300 
 David Kravitz, CEO 
 Seymour Pierce               +44 (0)20 7107 8000 
 Sarah Jacobs / Mark Percy 
  (Corporate Finance) 
 David Banks (Corporate 
  Broking) 
 Financial Dynamics           +44 (0)20 7831 3113 
 Ben Brewerton 
 

About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a medical solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate, vascular resistance, and pressure every 10 seconds providing surgeons with additional data prior to transplant.

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is the global commercialization of its FDA cleared, CE marked, clinically validated, LifePort Kidney Transporter and related consumables. LifePorts for preservation of the liver, heart, lung and pancreas are in late stage pre-clinical development along with new proprietary solutions and medical accessories to help improve the preservation, evaluation, and transport of organs for transplantation.

For further information please see www.lifeline-scientific.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBKLFFLXFEBBL

Lifeline Sci. S (LSE:LSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Lifeline Sci. S (LSE:LSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024